vTv Therapeutics (VTVT)
(Delayed Data from NSDQ)
$14.62 USD
+0.14 (0.99%)
Updated Aug 5, 2025 03:00 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VTVT 14.62 +0.14(0.99%)
Will VTVT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTVT
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
VTVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VTVT
Tracking Baker Brothers Portfolio - Q1 2025 Update
vTv Therapeutics Holds 2025 Annual Stockholders Meeting
vTv Therapeutics (VTVT) Appoints New CFO | VTVT Stock News
vTv Therapeutics Appoints Michael Tung, M.D. ...
vTv Therapeutics appoints Michael Tung as CFO